213 related articles for article (PubMed ID: 12393641)
21. The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS.
Parker JE; Mufti GJ; Rasool F; Mijovic A; Devereux S; Pagliuca A
Blood; 2000 Dec; 96(12):3932-8. PubMed ID: 11090080
[TBL] [Abstract][Full Text] [Related]
22. [Quantitative Analysis on Immunophenotype of CD34
Chen X; Ren FG; Zhang YF; Xu J; Xia T; Chang JM; Chen XH; Tan YH; Wang HW; Xu ZF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Jun; 29(3):832-839. PubMed ID: 34105480
[TBL] [Abstract][Full Text] [Related]
23. [Immunologic characteristics and prognosis of acute myeloid leukemia M1].
Zhao F; Chen Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Aug; 15(4):687-91. PubMed ID: 17708783
[TBL] [Abstract][Full Text] [Related]
24. [Myelodysplastic syndromes (MDS). Aspects of hematopathologic diagnosis].
Schmitt-Graeff A; Mattern D; Köhler H; Hezel J; Lübbert M
Pathologe; 2000 Jan; 21(1):1-15. PubMed ID: 10663664
[TBL] [Abstract][Full Text] [Related]
25. Immunotyping of blasts in refractory anaemia with excess of blasts.
Oertel J; Kleiner S; Huhn D
Br J Haematol; 1993 Jun; 84(2):305-9. PubMed ID: 7691147
[TBL] [Abstract][Full Text] [Related]
26. [Study on the immunophenotypes of bone marrow cells from patients with myelodysplastic syndromes and its clinical implications].
Wang JY; Li XM; Li FJ; Chen XG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2002 Apr; 10(2):173-4. PubMed ID: 12513825
[TBL] [Abstract][Full Text] [Related]
27. More cell death in refractory anemia with excess blasts in transformation than in acute myeloid leukemia.
Huh YO; Jilani I; Estey E; Giles F; Kantarjian H; Freireich E; Albitar M
Leukemia; 2002 Nov; 16(11):2249-52. PubMed ID: 12399969
[TBL] [Abstract][Full Text] [Related]
28. Expression of the multidrug resistance P-glycoprotein and its relationship to hematological characteristics and response to treatment in myelodysplastic syndromes.
Lepelley P; Soenen V; Preudhomme C; Lai JL; Cosson A; Fenaux P
Leukemia; 1994 Jun; 8(6):998-1004. PubMed ID: 7516032
[TBL] [Abstract][Full Text] [Related]
29. Combined flow cytometric assessment of CD45, HLA-DR, CD34, and CD117 expression is a useful approach for reliable quantification of blast cells in myelodysplastic syndromes.
Sandes AF; Kerbauy DM; Matarraz S; Chauffaille Mde L; López A; Orfao A; Yamamoto M
Cytometry B Clin Cytom; 2013 May; 84(3):157-66. PubMed ID: 23475532
[TBL] [Abstract][Full Text] [Related]
30. Myeloid enzymes profile related to the immunophenotypic characteristics of blast cells from patients with acute myeloid leukemia (AML) at diagnosis.
Klobusicka M; Kusenda J; Babusikova O
Neoplasma; 2005; 52(3):211-8. PubMed ID: 15875082
[TBL] [Abstract][Full Text] [Related]
31. Cytogenetic analogy between myelodysplastic syndrome and acute myeloid leukemia of elderly patients.
Rossi G; Pelizzari AM; Bellotti D; Tonelli M; Barlati S
Leukemia; 2000 Apr; 14(4):636-41. PubMed ID: 10764149
[TBL] [Abstract][Full Text] [Related]
32. Acute myeloid leukemia with t(6;9) (p23;q34): association with myelodysplasia, basophilia, and initial CD34 negative immunophenotype.
Alsabeh R; Brynes RK; Slovak ML; Arber DA
Am J Clin Pathol; 1997 Apr; 107(4):430-7. PubMed ID: 9124211
[TBL] [Abstract][Full Text] [Related]
33. Primary myelodysplastic syndromes: diagnostic and prognostic significance of immunohistochemical assessment of bone marrow biopsies.
Mangi MH; Mufti GJ
Blood; 1992 Jan; 79(1):198-205. PubMed ID: 1370203
[TBL] [Abstract][Full Text] [Related]
34. Proliferation and differentiation of myelodysplastic CD34+ cells: phenotypic subpopulations of marrow CD34+ cells.
Sawada K; Sato N; Notoya A; Tarumi T; Hirayama S; Takano H; Koizumi K; Yasukouchi T; Yamaguchi M; Koike T
Blood; 1995 Jan; 85(1):194-202. PubMed ID: 7528567
[TBL] [Abstract][Full Text] [Related]
35. Imbalance between apoptosis and telomerase activity in myelodysplastic syndromes: possible role in ineffective hemopoiesis.
Ohshima K; Karube K; Shimazaki K; Kamma H; Suzumiya J; Hamasaki M; Kikuchi M
Leuk Lymphoma; 2003 Aug; 44(8):1339-46. PubMed ID: 12952227
[TBL] [Abstract][Full Text] [Related]
36. [Immunophenotyping in myelodysplastic syndromes].
Chen G; Shao Z; Zhang Y
Zhonghua Xue Ye Xue Za Zhi; 1999 Jan; 20(1):14-6. PubMed ID: 11498836
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of apoptosis as a prognostic factor in myelodysplastic syndromes.
Shimazaki K; Ohshima K; Suzumiya J; Kawasaki C; Kikuchi M
Br J Haematol; 2000 Sep; 110(3):584-90. PubMed ID: 10997968
[TBL] [Abstract][Full Text] [Related]
38. Enhanced myeloid specificity of CD117 compared with CD13 and CD33.
Nomdedéu JF; Mateu R; Altès A; Llorente A; Rio C; Estivill C; López O; Ubeda J; Rubiol E
Leuk Res; 1999 Apr; 23(4):341-7. PubMed ID: 10229319
[TBL] [Abstract][Full Text] [Related]
39. Immunophenotypic characterization of myelopoiesis in early and late myelodysplastic syndromes: use of CD44 as an aid in early diagnosis.
Karmon Y; Manaster J; Chezar J
Cytometry; 2002 Aug; 50(4):225-30. PubMed ID: 12210602
[TBL] [Abstract][Full Text] [Related]
40. Effect of thrombopoietin on proliferation of blasts from patients with myelodysplastic syndromes.
Luo SS; Ogata K; Yokose N; Kato T; Dan K
Stem Cells; 2000; 18(2):112-9. PubMed ID: 10742383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
